UCB SA (LON:0NZT)

Market Cap	39.88B +53.0%
Revenue (ttm)	6.75B +25.8%
Net Income	1.36B +46.3%
EPS	7.01 +46.5%
Shares Out	n/a
PE Ratio	29.34
Forward PE	22.44
Dividend	0.88 (0.38%)
Ex-Dividend Date	May 4, 2026

Volume	21,751
Average Volume	114,284
Open	234.00
Previous Close	233.71
Day's Range	232.50 - 236.90
52-Week Range	146.40 - 289.50
Beta	0.17
RSI	40.15
Earnings Date	Jul 30, 2026

About UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1925
• Employees: 9,765
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0NZT

Financial Performance

In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.

Financial numbers in EUR